NCT03364231View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

February 15, 2022

Study Completion Date

February 15, 2022

Conditions

Marginal Zone LymphomaWaldenstrom MacroglobulinemiaNon Follicular Indolent Non-Hodgkin Lymphoma

Interventions

DRUG

Umbralisib

Oral Daily Dose

Trial Locations (4)

10065

TG Therapeutics Investigational Trial Site, New York

20007

TG Therapeutics Investigational Trial Site, Washington D.C.

02215

TG Therapeutics Investigational Trial Site, Boston

07601

TG Therapeutics Investigational Trial Site, Hackensack

All Listed Sponsors

lead

TG Therapeutics, Inc.

INDUSTRY

NCT03364231 - Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter